Smith & Nephew SNATS's (SNN) Hold (C+) Rating Reaffirmed at Weiss Ratings

Key Points

• Smith & Nephew SNATS's stock received a "hold (C+)" rating from Weiss Ratings, while other firms have given varied ratings ranging from "outperform" to "market perform."
• The stock currently has an average price target of $36.75 and is trading near $36.59 with a market cap of $15.62 billion.
• Recent activity among hedge funds indicates increased interest, with several firms significantly increasing their holdings in Smith & Nephew SNATS shares.

Smith & Nephew SNATS (NYSE:SNN - Get Free Report)'s stock had its "hold (c+)" rating reiterated by equities research analysts at Weiss Ratings in a research note issued to investors on Friday,Weiss Ratings reports.

A number of other research firms have also weighed in on SNN. Royal Bank Of Canada reiterated an "outperform" rating on shares of Smith & Nephew SNATS in a research report on Monday. Sanford C. Bernstein set a $37.50 price target on shares of Smith & Nephew SNATS and gave the stock a "market perform" rating in a research report on Tuesday, October 14th. Canaccord Genuity Group upped their price target on shares of Smith & Nephew SNATS from $28.00 to $36.00 and gave the stock a "hold" rating in a research report on Monday, August 18th. Finally, Wall Street Zen lowered shares of Smith & Nephew SNATS from a "strong-buy" rating to a "buy" rating in a research report on Friday, October 3rd. One research analyst has rated the stock with a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $36.75.

Smith & Nephew SNATS Stock Performance

Shares of NYSE SNN opened at $36.59 on Friday. The firm has a market capitalization of $15.62 billion, a price-to-earnings ratio of 16.94, a price-to-earnings-growth ratio of 0.99 and a beta of 0.69. Smith & Nephew SNATS has a 12-month low of $23.69 and a 12-month high of $38.79. The firm has a 50 day moving average of $36.73 and a 200 day moving average of $32.05. The company has a current ratio of 3.00, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60.

Hedge Funds Weigh In On Smith & Nephew SNATS

Hedge funds have recently modified their holdings of the stock. Hexagon Capital Partners LLC lifted its holdings in shares of Smith & Nephew SNATS by 63.3% in the first quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider's stock worth $30,000 after buying an additional 406 shares in the last quarter. Richards Merrill & Peterson Inc. lifted its holdings in shares of Smith & Nephew SNATS by 500.0% in the first quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider's stock worth $34,000 after buying an additional 1,000 shares in the last quarter. AlphaCore Capital LLC purchased a new position in shares of Smith & Nephew SNATS in the second quarter worth $44,000. Bessemer Group Inc. lifted its holdings in shares of Smith & Nephew SNATS by 3,471.4% in the first quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock worth $49,000 after buying an additional 1,701 shares in the last quarter. Finally, Banque Transatlantique SA purchased a new position in shares of Smith & Nephew SNATS in the first quarter worth $52,000. Hedge funds and other institutional investors own 25.64% of the company's stock.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.